@article{VandeKerkhofFeenstravanderHeijdenetal.2012,
  author    = {Van de Kerkhof, Noortje W. A. and Feenstra, Ilse and van der Heijden, Frank M. M. A. and de Leeuw, Nicole and Pfundt, Rolph and St{\"o}ber, Gerald and Egger, Jos I. M. and Verhoeven, Willem M. A.},
  title     = {Copy number variants in a sample of patients with psychotic disorders: is standard screening relevant for actual clinical practice?},
  series = {Neuropsychiatric Disease and Treatment},
  volume    = {8},
  journal   = {Neuropsychiatric Disease and Treatment},
  doi       = {10.2147/NDT.S32903},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-134769},
  pages     = {295-300},
  year      = {2012},
  abstract  = {With the introduction of new genetic techniques such as genome-wide array comparative genomic hybridization, studies on the putative genetic etiology of schizophrenia have focused on the detection of copy number variants (CNVs), ie, microdeletions and/or microduplications, that are estimated to be present in up to 3\% of patients with schizophrenia. In this study, out of a sample of 100 patients with psychotic disorders, 80 were investigated by array for the presence of CNVs. The assessment of the severity of psychiatric symptoms was performed using standardized instruments and ICD-10 was applied for diagnostic classification. In three patients, a submicroscopic CNV was demonstrated, one with a loss in 1q21.1 and two with a gain in 1p13.3 and 7q11.2, respectively. The association between these or other CNVs and schizophrenia or schizophrenia-like psychoses and their clinical implications still remain equivocal. While the CNV affected genes may enhance the vulnerability for psychiatric disorders via effects on neuronal architecture, these insights have not resulted in major changes in clinical practice as yet. Therefore, genome-wide array analysis should presently be restricted to those patients in whom psychotic symptoms are paired with other signs, particularly dysmorphisms and intellectual impairment.},
  language  = {en}
}
@article{KittelSchneiderDavidovaKaloketal.2022,
  author    = {Kittel-Schneider, Sarah and Davidova, Petra and Kalok, Miriam and Essel, Corina and Ahmed, Fadia Ben and Kingeter, Yasmina and Matentzoglu, Maria and Leutritz, Anna and Kersken, Katharina and Koreny, Carolin and Weber, Heike and Kollert, Leoniee and McNeill, Rihannon V. and Reif, Andreas and Bahlmann, Franz and Trautmann-Villalba, Patricia},
  title     = {A pilot study of multilevel analysis of BDNF in paternal and maternal perinatal depression},
  series = {Archives of Women's Mental Health},
  volume    = {25},
  journal   = {Archives of Women's Mental Health},
  number    = {1},
  issn      = {1435-1102},
  doi       = {10.1007/s00737-021-01197-2},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-268849},
  pages     = {237-249},
  year      = {2022},
  abstract  = {Depression in the perinatal period is common in mothers worldwide. Emerging research indicates that fathers are also at risk of developing perinatal depression. However, knowledge regarding biological risk factors and pathophysiological mechanisms of perinatal depression is still scarce, particularly in fathers. It has been suggested that the neurotrophin BDNF may play a role in maternal perinatal depression; however, there is currently no data regarding paternal perinatal depression. For this pilot study, 81 expecting parents were recruited and assessed at several time points. We screened for depression using EPDS and MADRS, investigated several psychosocial variables, and took blood samples for BDNF val66met genotyping, epigenetic, and protein analysis. Between pregnancy and 12 months postpartum (pp), we found that 3.7 to 15.7\% of fathers screened positive for depression, and 9.6 to 24\% of mothers, with at least a twofold increased prevalence in both parents using MADRS compared with EPDS. We also identified several psychosocial factors associated with perinatal depression in both parents. The data revealed a trend that lower BDNF levels correlated with maternal depressive symptoms at 3 months pp. In the fathers, no significant correlations between BDNF and perinatal depression were found. Pregnant women demonstrated lower BDNF methylation and BDNF protein expression compared with men; however, these were found to increase postpartum. Lastly, we identified correlations between depressive symptoms and psychosocial/neurobiological factors. The data suggest that BDNF may play a role in maternal perinatal depression, but not paternal.},
  language  = {en}
}